[1]孙硕,毛露,史虓悦,等.内皮素-1促进慢性心功能衰竭进展机制研究[J].心血管病学进展,2019,(6):927-930.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.022]
　SUN Shuo,MAO Lu,SHI Xiaoyue,et al.Mechanism of Endothelin-1 in Promoting Progression of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(6):927-930.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.022]
点击复制

内皮素-1促进慢性心功能衰竭进展机制研究(/HTML)
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年6期
页码:
927-930
栏目:
综述
出版日期:
2019-09-25

文章信息/Info

Title:
Mechanism of Endothelin-1 in Promoting Progression of Chronic Heart Failure
作者:
孙硕1; 毛露2; 史虓悦1; Dirk Hermann3;  陈艾东1; 3 *
(1.心血管病靶向干预重点实验室 南京医科大学,江苏 南京 211166;2.东南大学附属中大医院 东南大学,江苏 南京 21 0096;3.神经生物学研究中心 杜伊斯堡-埃森大学,德国 埃森 45122)
Author(s):
SUN Shuo 1;  MAO Lu 2;  SHI Xiaoyue1;  Dirk Hermann3;  CHEN Aidong 1; 3
(1.Key Laboratory of Targeting Interventions for Cardiovascular Diseases, Nanjing Medical University, Nanjing 211166,Jiangsu, China; 2.Zhongda Hospital Affiliated to Southeast University, Southeast University, Nanjing 210096,Jiangsu, China; 3.Center for Neurobiology, Duisburg -Essen University, Essen 45122, Germany)?
Funded by: National Natural Science Foundation of China (31571168) National Public Fund for Study Abroad (20173059)
Keywords:
Endothelin-1;  Chronic heart failure;  Receptor antagonist
DOI:
10.16806/j.cnki.issn.1004-3934.2019.06.022
摘要:

内皮素-1是一种21个氨基酸的肽，为目前发现的最强的血管收缩和升压物。慢性心功能衰竭时，内皮素-1浓度升高，其对心肌细胞具有直接毒性、强烈的正性肌力作用、致使心肌细胞肥大活性和诱导室性心律失常等效应，参与慢性心功能衰竭的恶化进展。内皮素-1通过激活两种受体亚型内皮素-1A和内皮素-1B受体起作用，这两种受体亚型根据细胞类型与各种GTP结合蛋白偶联，发挥相应的生物学效应。内皮素-1拮抗剂有望成为慢性心功能衰竭治疗新靶点。现就内皮素-1促进慢性心功能衰竭进展机制做一综合阐述，旨在为本病的治疗梳理出新的治疗靶点。

Abstract:
Endothelin-1 (ET-1) is a 21 amino acid peptide that is the strongest vasoconstrictor and booster pressor substance found so far. In chronic heart failure, the concentration of ET-1 increased, which is directly toxic to cardiomyocytes, and causes strong positive inotropic effects. It can cause cardiomyocyte hypertrophy,induce ventricular arrhythmia,and participate in chronic cardiac dysfunction. ET-1 acts by activating two receptor subtypes, ET A and ET B receptors, which are conjugated to various GTP-binding proteins depending on the cell type, exerting corresponding biological effects. ET-1 antagonists are expected to become new drug targets for the treatment of chronic heart failure. In this paper, a comprehensive review on the progress of ET-1 in promoting the progression of chronic heart failure is aimed at combing a new therapeutic target for the treatment of this disease.

参考文献/References:

[1] Ibrahim NE, Gupta R, Lyass A, et al. Endothelin-1 measurement in patients undergoing diagnostic coronary angiography—results from the catheter sampled blood archive in cardiovascular diseases study[J]. Clin Chem,2018,64(11):1617-1625.

[2] Wang S,Guo X,Long CL ,et al. SUR2B/Kir6.1 channel openers correct endothelial dysfunction in?chronic heart failure?via the miR-1-3p/ET-1?pathway[J].Biomed Pharmacother,2019,110(2):431-439.

[3] Yang S,Liu Z,Liu S ,et al. Association of baseline big endothelin-1 level with long-term prognosis among cardiac resynchronization therapy recipients[J].Clin Biochem,2018,59:25-30.

[4] Peng T,Li X,Hu Z ,et al. Predictive role of endothelin in left ventricular remodeling of?chronic?kidney disease[J]. Ren Fail ,2018,40(1):183-186.

[5] Smyrnias I,Goodwin N,Wachten D, et al. Contractile responses to endothelin-1 are regulated by PKC phosphorylation of cardiac myosin binding protein-C in rat ventricular myocytes[J].J Mol Cell Cardiol,2018,117(2):1-18.

[6] Zhang CL,Xie S,Qiao X,et al. Plasma endothelin-1-related peptides as the prognostic biomarkers for?heart failure:A PRISMA-compliant meta-analysis[J]. Medicine(Baltimore) , 2017,96(50):e9342.

[7] Barta T,Tosaki A,Haines D,et al. Endothelin-1-induced hypertrophic alterations and heme oxygenase-1 expression in cardiomyoblasts are counteracted by beta estradiol:in vitro and in vivo studies[J].Naunyn Schmiedebergs Arch Pharmacol,2018,391(4):371-383.

[8] Meoli DF,Su YR,Brittain EL,et al. The transpulmonary ratio of endothelin 1 is elevated in patients with preserved left ventricular ejection fraction and combined pre- and post-capillary pulmonary hypertension[J].Pulm Circ,2018,8(1):2045893217745019.

[9] Yim J, Cho H, Rabkin SW. Gene expression and gene associations during the development of?heart failure?with preserved ejection fraction in the Dahl salt sensitive model of hypertension[J].Clin Exp Hypertens,2018,40(2):155-166.

[10] Guo B, Li Y, Jin X, et al. Nitric oxide/cyclic GMP pathway mediates the endothelin-1-upregulation of adiponectin expression in rat cardiomyocytes[J].

Biomed Rep,2017,7(3):267-271.

[11] Jacques D, D’Orléans-Juste P, Magder S, et al. Neuropeptide Y and its receptors in ventricular endocardial endothelial cells[J]. Can J Physiol Pharmacol ,2017,95(10):1224-1229.

[12] Yuzugulen J, Douthwaite JA,Wood EG, et al. Characterisation of preproendothelin-1 derived peptides identifies endothelin-like domain peptide as a modulator of endothelin-1[J].Sci Rep,2017,7(1):4956.

[13] Buendgens L, Yagmur E, Bruensing J, et al. C-terminal proendothelin-1(CT-proET-1) is associated with organ?failure?and predicts mortality in critically ill patients[J].J Intensive Care,2017,5:25.

[14] Lin J, Chudasama N, Hayashi Y, et al. Peripheral venous congestion causes time- and dose-dependent release of endothelin-1 in humans[J]. Physiol Rep ,2017,5(6).pii: e13118.

[15] Jin F. Analysis on mechanism of ATP-sensitive K+?channel opener natakalim improving congestive?heart failure?after myocardial infarction[J]. Exp Ther Med ,2016,12(6):3993-3997.

[16]Valero-Munoz M, Li S, Wilson RM, et al. Dual endothelin-A/endothelin-B receptor blockade and cardiac remodeling in?heart failure?with preserved ejection fraction[J]. Circ?Heart?Fail ,2016,9(11).pii: e003381.

[17] 王灵冰,滕欣越,张瑞,等.慢性心力衰竭与血管紧张素Ⅱ相关性分子机制研究进展[J].心血管病学进展,2018,39(6):963-966.

[18] Miyamoto K,Takeuchi D,Inai K,et al. Prognostic value of multiple biomarkers for cardiovascular mortality in adult congenital?heart disease:comparisons of single-/two-ventricle physiology,and systemic morphologically right/left ventricles[J].Heart?Vessels, 2016,31(11):1834-1847.

[19] Gergei I, Kr?mer BK, Scharnagl H, et al. Propeptide big-endothelin, N-terminal-pro brain natriuretic peptide and mortality. The Ludwigshafen risk and cardiovascular health(LURIC) study[J].Biomarkers,2017,22(3-4):315-320.

[20] Jen HL,Yin WH,Chen JW,et al. Endothelin-1-induced cell hypertrophy in cardiomyocytes is improved by fenofibrate: possible roles of adiponectin[J]. J Atheroscler Thromb ,2017,24(5):508-517.

[21] Seidlmayer LK, Kuhn J, Berbner A, et al.Inositol 1,4,5-trisphosphate-mediated sarcoplasmic reticulum-mitochondrial crosstalk influences adenosine triphosphate production via mitochondrial Ca2+ uptake through the mitochondrial ryanodine receptor in cardiac myocytes[J]. Cardiovasc Res ,2016,112(1):491-501.

[22] Packer M,McMurray JJV,Krum H,?et al. Long-term?effect?of endothelin?receptor?antagonism?with?bosentan?on the?morbidity?and?mortality?of?patients?with?severe?chronic?heart?failure:primary?results?of the?ENABLE?trials[J]. JACC?Heart?Fail,2017,5(5):317-326.

备注/Memo

备注/Memo:
通讯作者:陈艾东，E-mail:aidongchen@njmu.edu.cn?收稿日期：2019-03-12
基金项目: 国家自然科学基金面上项目( 31571168,30870908，81571246)；国家公派留学基金（20173059)
更新日期/Last Update: 2019-12-17